UroGen Pharma Ltd. (URGN) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very high margin ⢠Ample liquidity buffer ⢠Persistent cash burn Urgent (URGN) combines very high gross margins and strong near-term liquidity with persistent operating losses, heavy cash burn and high leverage that materially weaken its premium valuation.
Price Behavior
Key Price Behavior Insights: ⢠Uptrend last month ⢠Extended above SMA ⢠Resistance near high Support Level: $17.00â$18.50 Resistance Level: $22.30 URGN is in a clear uptrend over the last month, trading well above its shortâterm moving average (showing momentum but shortâterm overextension) with support around $17.00â$18.50 and immediate resistance near $22.30.
Sentiment & News
Key News Insights: ⢠Durable efficacy ⢠High early CR ⢠Physician engagement UroGen's ENVISION data showed a 72.2% 24âmonth eventâfree probability after a 79.6% CR at 3 months for ZUSDURI in lowâgrade UTUC, and the company launched the LGâUTUC Luminaries Initiative to bolster physician engagement and disease awareness. #LG-UTUCâ
AI Summary
URGN has meaningfully shifted from a binary clinical bet to a commercial-stage, dual-product revenue storyâENVISION durability data and a permanent Jâcode deârisk clinical upside and make rapid conversion of physician demand into billed doses the critical value inflection. The key actionable risk is execution: monitor PEFâtoâdose timelines, quarterâoverâquarter recognized revenue growth (not just demand), and cash burn relative to runway, because missed conversion or another dilutive raise would materially compress valuation.
Description
UroGen Pharma Ltd. is a biotechnology company developing treatments for urothelial diseases and specialty cancers, using a biocompatible reverse thermal gel platform to modify drug delivery and exposure. Its pipeline includes UGN-102, currently in Phase III for several forms of non-muscle invasive urothelial cancer, and UGN-301 for high-grade disease, alongside a commercial offering based on its hydrogel technology. The company maintains licensing and development agreements with Allergan and Agenus and a research collaboration with MD Anderson, and is based in Princeton, New Jersey (incorporated 2004).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 21 | Jul 28 | URGN | UroGen Pharma Ltd. | UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points. | Closed | +22.3% |